Episode
Episode 142: Myeloma Series, Pt.3 - Management of Smoldering Multiple Myeloma (2025)
- Published
- Dec 17, 2025
- Processing state
not_requested- Canonical source
- https://www.thefellowoncall.com/tfocpodcast/smolderingmyeloma
Actions
POST https://stenobird.com/v1/public/podcasts/the-fellow-on-call-the-heme-onc-podcast-4669989/episodes/episode-142-myeloma-series-pt-3-management-of-smoldering-multiple-myeloma-2025/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-fellow-on-call-the-heme-onc-podcast-4669989/episode-142-myeloma-series-pt-3-management-of-smoldering-multiple-myeloma-2025.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
The way that we think about smoldering multiple myeloma (SMM) has continued to see evolution in the plasma cell dyscrasia space. If this diagnosis portends a higher risk of developing multiple myeloma, how should we manage patients to prevent possible end-organ damage? Is it a one-size-fits-all approach or are there some patients who are higher risk for progression than others? We cover this and so much more in this new episode! This episode is brought to you by Primum Content: - What is smoldering multiple myeloma (SMM)? - What are higher risk features of SMM? - What are landmark studies in SMM? - To treat or not to treat? ** This episode is brought to you by Primum: http://primum.co/fellows ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms! Twitter: @TheFellowOnCall Instagram: @TheFellowOnCall Listen in on: Apple Podcast, Spotify, and Youtube